Showing results (71-80 of 331) with videos related to

Sort By:
Pageof 34
Seminars in Cutaneous Medicine and Surgery|July 25, 2018
Biomarkers for immune therapy in melanomaDouglas B Johnson, Jeewon Chon, Mark R Johnson, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 30, 2020
Balancing Cancer Immunotherapy Efficacy and ToxicityDouglas B Johnson, Baruch D Jakubovic, Vincent Sibaud, et al.
The Oncologist|October 26, 2022
Recurrence of Hypophysitis After Immune Checkpoint Inhibitor RechallengeBenjamin C Park, Seungyeon Jung, Jordan J Wright, et al.
Immunological Reviews|July 20, 2023
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunitiesRachel S Goodman, Seungyeon Jung, Justin M Balko, et al.
The Oncologist|June 20, 2019
Empiric Therapy with BRAF and MEK Inhibitors in Metastatic MelanomaChristopher G Cann, Benjamin F Tillman, Elizabeth J Davis, et al.
Cancer Immunology Research|July 5, 2024
Unveiling Cellular Identities and Gene Expression Pathways in Overlapping Myocarditis and MyositisReilly G Fankhauser, Douglas B Johnson, Javid J Moslehi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 23, 2018
Biological Consequences of MHC-II Expression by Tumor Cells in CancerMargaret L Axelrod, Rebecca S Cook, Douglas B Johnson, et al.
Nature Reviews. Clinical Oncology|January 18, 2022
Harnessing big data to characterize immune-related adverse eventsYing Jing, Jingwen Yang, Douglas B Johnson, et al.
Immunology and Allergy Clinics of North America|April 26, 2022
Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and ModelsBenjamin C Park, Cosby A Stone, Anna K Dewan, et al.
Nature Reviews. Clinical Oncology|January 27, 2022
Immune-checkpoint inhibitors: long-term implications of toxicityDouglas B Johnson, Caroline A Nebhan, Javid J Moslehi, et al.
Pageof 34